Literature DB >> 8501176

Effects of gonadotrophin-releasing hormone agonists (GnRHa) on follicle and oocyte quality.

J Testart1, B Lefevre, A Gougeon.   

Abstract

This review summarizes the main clinical and research studies on direct and indirect effects of gonadotrophin-releasing hormone agonists (GnRHa) on follicles and oocytes in animals and humans. There is evidence for extra-pituitary actions of GnRHa, especially on follicle growth, follicular steroidogenesis, and oocyte meiotic maturation. Different effects have been reported from using various GnRHa molecules. However, a direct effect of GnRHa on oocyte quality in gonadotrophin stimulated cycles has not yet been demonstrated. Observed high pregnancy rates per ovarian puncture in in-vitro fertilization cycles using GnRHa, at least in long protocols, might result from higher numbers of oocytes recovered following administration of large doses of gonadotrophins, despite the fact that these oocytes may have a lower ability to fertilize and grow. Although there are obvious clinical advantages of using GnRHa for ovarian stimulation, more studies are needed to clarify the effects of these treatments at ovarian and uterine levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501176     DOI: 10.1093/oxfordjournals.humrep.a138086

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Effectiveness of low dose of gonadotropin releasing hormone agonist on hormonal flare-up.

Authors:  B Bständig; I Cédrin-Durnerin; J N Hugues
Journal:  J Assist Reprod Genet       Date:  2000-02       Impact factor: 3.412

Review 2.  Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.

Authors:  Luiz Eduardo T Albuquerque; Leopoldo O Tso; Humberto Saconato; Maria Cecília R M Albuquerque; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

3.  Evaluation of two gonadotropin-releasing hormone (GnRH) analogues (leuprolide and buserelin) in short and long protocols for assisted reproduction techniques.

Authors:  B C Tarlatzis; G Grimbizis; F Pournaropoulos; J Bontis; S Lagos; G Pados; S Mantalenakis
Journal:  J Assist Reprod Genet       Date:  1994-02       Impact factor: 3.412

4.  Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles.

Authors:  Ensieh Sh Tehraninejad; Elham Azimi Nekoo; Zahra Ezabadi; Batool H Rashidi; Elham Amirchaghmaghi; Elham Pour Matroud
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

5.  De novo transcriptome assembly from the gonads of a scleractinian coral, Euphyllia ancora: molecular mechanisms underlying scleractinian gametogenesis.

Authors:  Yi-Ling Chiu; Shinya Shikina; Yuki Yoshioka; Chuya Shinzato; Ching-Fong Chang
Journal:  BMC Genomics       Date:  2020-10-21       Impact factor: 3.969

6.  No significant long-term complications from inadvertent exposure to gonadotropin-releasing hormone agonist during early pregnancy in mothers and offspring: a retrospective analysis.

Authors:  Huan Wu; Xiaoyan Xu; Cong Ma; Yiran Zhou; Shanai Pei; Hao Geng; Ye He; Qianhua Xu; Yuping Xu; Xiaojin He; Ping Zhou; Zhaolian Wei; Xiaofeng Xu; Yunxia Cao
Journal:  Reprod Biol Endocrinol       Date:  2021-03-20       Impact factor: 5.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.